Microsomal prostaglandin e synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2247-2255

  Beales, Ian L P ^a,b   Ogunwobi, Olorunseun O ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Barrett's oesophagus; Celecoxib; Cyclo oxygenase; Leptin; Prostacyclin; Prostaglandins

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 4 (BENZO[B]THIOPHEN 2 YL) 3 BROMO 5 HYDROXYDIHRODROFURAN 2(3H)ONE; CAY 10526; CELECOXIB; CYCLOOXYGENASE 2; ENZYME INHIBITOR; LEPTIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTACYCLIN; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ISOMERASE; PROSTAGLANDIN E SYNTHASE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RNA INTERFERENCE; VASCULAR ENDOTHELIUM; ADENOCARCINOMA; BIOSYNTHESIS; CELL SURVIVAL; DRUG ANTAGONISM; ENDOTHELIUM CELL; ESOPHAGUS TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; EPOPROSTENOL; ESOPHAGEAL NEOPLASMS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LEPTIN; PYRAZOLES; RNA, SMALL INTERFERING; SULFONAMIDES;

EID: 77949910118     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24875     Document Type: Article

References (41)

1. Mann JR, Dubois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004; 10:145-152
2. Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 2004;43:3-35.
3. Sheng H, Shao J, Washington MK, Dubois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-18081
4. Hawcroft G, Ko CW, Hull MA. Prostaglandin E(2)-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007;26:3006-3019
5. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442
6. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15:2057-2072
7. Ogunwobi OO, Beales IL. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase. JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 2007;22: 401-409
8. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002;277: 27613-27621
9. Liu JF, Zhu GJ, Jamieson GG, Wu TC, Zhu TN, Shan BE, Drew PA. NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2. Cancer Invest 2009;27:17-23.
10. Chiou SK, Tanigawa T, Akahoshi T, Abdelkarim B, Jones MK, Tarnawski AS. Survivin: a novel target for indomethacin-induced gastric injury. Gastroenterology 2005;128:63-73.
11. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3: 1679-1683
12. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, Siegert A, Hauptmann S. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 2003;22:8653-8661
13. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G, Grosch S. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008;76:179-187
14. Yu HP, Shi LY, Lu WH, Su YH, Li YY, Xu SQ. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor. NS-398. J Gastroenterol Hepatol 2004;19:638-642
15. Vona-Davis L, Riggs DR, Jackson BJ, McFadden DW. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro. J Surg Res 2004;119:143-148
16. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080
17. Grosser T, Fries S, Fitzgerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
18. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007; 59:207-214
19. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001;167:2831-2838
20. Houliston R, Keogh R, Sugden D, Dudhia J, Carter T, Wheeler-Jones C. Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Throm Haemost 2002;88: 321-328
21. Syeda F, Grosjean J, Houliston R, Keogh R, Carter T, Paeolog E, Wheeler-Johns C. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-jB pathways. J Biol Chem 2006;281:11792-11804
22. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, Lutzke LS. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002;94:422-429
23. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60: 5767-5772
24. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-1112
25. Song S, Guha S, Liu K, Buttar NS, Bresalier RS. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007;56:1512-1521
26. Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol. Cell Endocrinol 2007;274: 60-68
27. Ogunwobi OO, Beales IL. Glycine-extended gastrin stimulates proliferation via JAK2-and Akt-dependent NF-kappaB activation in Barrett's oesophageal adenocarcinoma cells. Mol Cell Endocrinol 2008;296:94-102.
28. Beales I, Ogunwobi O. Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. J Mol Endocrinol 2009; 42:305-318
29. Jang TJ, Min SK, Bae JD, Jung KH, Lee JI, Kim JR, Ahn WS. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux. Gut 2004;53:27-33.
30. von Rahden BH, Stein HJ, Hartl SA, Theisen J, Stigler B, Siewert JR, Sarbia M. Expression of prostaglandin E synthase in Barrett's cancer. Dis Esophagus 2008;21: 304-308
31. Guerrero MD, Aquino M, Bruno I, Terencio MC, Paya M, Riccio R, Gomez-Paloma L. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. J Med Chem 2007; 50:2176-2184
32. Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K, Lavigne M, Fahmi H. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membraneassociated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 2004;279:22057-22065
33. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006;147: 4505-4516
34. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825-837
35. Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008;285: 43-50.
36. Uracz W, Uracz D, Olszanecki R, Gryglewski RJ. Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells. J Physiol Pharmacol 2002;53:643-654
37. Beales IL, Ogunwobi OO, Cameron E, El-Amin K, Mutungi G, Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a functional and immunohistochemical study. BMC Cancer 2007;7:97.
38. Cheong E, Ivory K, Doleman J, Parker ML, Rhodes M, Johnson IT. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 2004;25: 1945-1952.
39. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96: 272-277
40. Wheeler-Jones C. Regulation of endothelial prostacyclin synthesis by protease-activated receptors: mechanisms and significance. Pharmacol Rep 2008;60:109-118.
41. Xu D, Rowland SE, Clark P, Giroux A, Cote B, Guiral S, Salem M, Ducharme Y, Friesen RW, Methot N, Mancini J, Audoly L, et al. MF63 [2-(6-chloro-1H- phenanthro[9,10-d]imidazol-2-yl)-isophtha-lonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008;326:754-763